necitumumab   Click here for help

GtoPdb Ligand ID: 8090

Synonyms: 11F8 | IMC-11F8 | LY3012211 | Portrazza®
Approved drug
necitumumab is an approved drug (FDA (2015), EMA (2016))
Compound class: Antibody
Comment: Necitumumab is a monoclonal antibody with clinical antineoplastic action [1-3].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Click here for help
1. Liu M, Zhu Z. (2009)
Used in treating neoplastic diseases and hyperproliferative disorders.
Patent number: US7598350. Assignee: Imclone Llc. Priority date: 19/03/2004. Publication date: 06/10/2009.
2. Sacco PC, Maione P, Rossi A, Sgambato A, Casaluce F, Palazzolo G, Gridelli C. (2015)
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Expert Rev Respir Med, 9 (3): 245-54. [PMID:25797462]
3. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G et al.. (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol, 16 (7): 763-74. [PMID:26045340]